Completed OBSERVATIONAL NCT00681850

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment. (Optimise)

Sponsor: AstraZeneca

Conditions Diabetes

Updated 8 times since 2017 Last updated: Jan 21, 2020 Started: Mar 31, 2008 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Diabetes, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Feb 2020 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalst, Belgium , Aarschot, Belgium , Agrinio, Greece , Aldershot, United Kingdom , Alexandroupoli, Greece , Alsemberg, Belgium , Amaliáda, Greece , Amay, Belgium , Antoing, Belgium and 242 more locations